Talaris Therapeutics, Inc. (TALS): Price and Financial Metrics
GET POWR RATINGS... FREE!
TALS Stock Price Chart Interactive Chart >
TALS Price/Volume Stats
| Current price | $7.37 | 52-week high | $19.82 |
| Prev. close | $7.10 | 52-week low | $5.70 |
| Day low | $7.04 | Volume | 49,500 |
| Day high | $7.55 | Avg. volume | 46,603 |
| 50-day MA | $8.12 | Dividend yield | N/A |
| 200-day MA | $11.68 | Market Cap | 305.52M |
Talaris Therapeutics, Inc. (TALS) Company Bio
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.
Latest TALS News From Around the Web
Below are the latest news stories about Talaris Therapeutics Inc that investors may wish to consider to help them evaluate TALS as an investment opportunity.
Talaris Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare ConferenceBOSTON and LOUISVILLE, Ky., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 8:40 AM ET. |
We're Hopeful That Talaris Therapeutics (NASDAQ:TALS) Will Use Its Cash WiselyWe can readily understand why investors are attracted to unprofitable companies. For example, although... |
Altium Wealth Management LLC Buys Vanguard FTSE Emerging Markets ETF, Invesco Variable Rate ...Investment company Altium Wealth Management LLC (Current Portfolio) buys Vanguard FTSE Emerging Markets ETF, Invesco Variable Rate Preferred ETF, Charles Schwab Corp, Hartford Municipal Opportunities ETF, Talaris Therapeutics Inc, sells Banco Santander SA, Federal Realty Investment Trust, Sysco Corp, Rockwell Automation Inc, iShares MSCI EAFE Small-Cap ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Altium Wealth Management LLC. |
Talaris Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare ConferenceBOSTON and LOUISVILLE, Ky., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 2:15 PM ET. A live webcast o |
Talaris Therapeutics to Present at the H.C. Wainwright BioConnect 2022 Virtual ConferenceBOSTON and LOUISVILLE, Ky., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 10-13, 2022. A webcast of the pre-recorded pre |
TALS Price Returns
| 1-mo | 0.14% |
| 3-mo | N/A |
| 6-mo | -39.69% |
| 1-year | -44.38% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -51.80% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...